CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced additional data from its Phase 2 clinical trial of tivozanib (AV-951) - its oral, triple VEGF receptor inhibitor - in patients with advanced renal cell carcinoma (RCC). These data are being presented today at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), abstract number 5032.
